Translating to clinical practice, the important molecular subsets are based on the identification of a FLT3 mutation (30% of AML), NPM1 mutation (40–50% of normal karyotype AML), isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations (20% of AML), and TP53 mutations (2 to 20% of AML). Here, FLT3 is linked to acute myeloid leukemia.